Literature DB >> 12010967

Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity.

Dale Netski1, Thomas R Kozel.   

Abstract

Monoclonal antibodies (MAbs) reactive with glucuronoxylomannan (GXM), the major capsular polysaccharide of the yeast Cryptococcus neoformans, produce distinct capsular reactions when viewed by differential interference contrast microscopy. These reactions depend on the epitope specificity of the antibody. Opsonic activities of immunoglobulin G1 (IgG1) MAbs that produce patterns termed rim and puffy were examined. Rim-pattern MAbs are reactive with an epitope shared by GXM serotypes A, B, C, and D. Puffy-pattern MAbs are reactive only with serotypes A and D. In phagocytosis assays, using serotype A cells and resident murine peritoneal macrophages, rim-pattern MAbs were markedly more opsonic than puffy-pattern MAbs. F(ab')(2) fragments of rim-pattern MAbs were synergistic with heat-labile factors in normal human serum for opsonization of the yeast. F(ab')(2) fragments of puffy-pattern MAbs were also synergistic with normal serum in opsonization but at a much lower level than fragments of rim-pattern MAbs. Normal serum alone was not opsonic. F(ab')(2) fragments of rim-pattern MAbs, but not puffy-pattern MAbs, stimulated phagocytosis of encapsulated cryptococci in the absence of serum. This serum-independent opsonic action of F(ab')(2) fragments was abrogated by pretreatment of macrophages with purified GXM, suggesting the involvement of a phagocyte GXM receptor. The results indicate that (i) there are multiple mechanisms by which anticapsular IgG MAbs facilitate phagocytosis of encapsulated cryptococci, (ii) some anti-GXM antibodies are opsonic in an Fc-independent manner, and (iii) opsonic activity correlates with the capsular reaction and occurs in an epitope-specific manner.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010967      PMCID: PMC127994          DOI: 10.1128/IAI.70.6.2812-2819.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

Review 1.  Fc receptors.

Authors:  J V Ravetch; J P Kinet
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

2.  Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.

Authors:  T R Kozel; B C deJong; M M Grinsell; R S MacGill; K K Wall
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

3.  Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans.

Authors:  T C MacGill; R S MacGill; A Casadevall; T R Kozel
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

4.  Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide.

Authors:  N Lendvai; A Casadevall; Z Liang; D L Goldman; J Mukherjee; L Zuckier
Journal:  J Infect Dis       Date:  1998-06       Impact factor: 5.226

5.  Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments.

Authors:  C P Taborda; A Casadevall
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

6.  Cytokine enhancement of complement-dependent phagocytosis by macrophages: synergy of tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor for phagocytosis of Cryptococcus neoformans.

Authors:  H L Collins; G J Bancroft
Journal:  Eur J Immunol       Date:  1992-06       Impact factor: 5.532

Review 7.  Polysaccharide antigens of the capsule of Cryptococcus neoformans.

Authors:  R Cherniak; J B Sundstrom
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

8.  Protective murine monoclonal antibodies to Cryptococcus neoformans.

Authors:  J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

9.  Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan.

Authors:  A Casadevall; M DeShaw; M Fan; F Dromer; T R Kozel; L A Pirofski
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

10.  Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans.

Authors:  T R Kozel; M A Wilson; J W Murphy
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

View more
  23 in total

Review 1.  Role of phagocytosis in the virulence of Cryptococcus neoformans.

Authors:  Maurizio Del Poeta
Journal:  Eukaryot Cell       Date:  2004-10

2.  Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformans.

Authors:  Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

3.  Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.

Authors:  Haijun Tian; Avi Groner; Marianne Boes; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

4.  Opsonic requirements for dendritic cell-mediated responses to Cryptococcus neoformans.

Authors:  Ryan M Kelly; Jianmin Chen; Lauren E Yauch; Stuart M Levitz
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

5.  Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages.

Authors:  Zong Liang Chang; Dale Netski; Peter Thorkildson; Thomas R Kozel
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

6.  Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule.

Authors:  Marcellene A Gates-Hollingsworth; Thomas R Kozel
Journal:  Mol Microbiol       Date:  2009-09-02       Impact factor: 3.501

7.  Aggregation of Streptococcus pneumoniae by a pneumococcal capsular polysaccharide-specific human monoclonal IgM correlates with antibody efficacy in vivo.

Authors:  Kevin Fabrizio; Catherine Manix; Allan J Guimaraes; Joshua D Nosanchuk; Liise-Anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2010-03-03

Review 8.  Cryptococcal interactions with the host immune system.

Authors:  Kerstin Voelz; Robin C May
Journal:  Eukaryot Cell       Date:  2010-04-09

9.  Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.

Authors:  Raymond M Duro; Dale Netski; Peter Thorkildson; Thomas R Kozel
Journal:  Clin Diagn Lab Immunol       Date:  2003-03

10.  Antibody action after phagocytosis promotes Cryptococcus neoformans and Cryptococcus gattii macrophage exocytosis with biofilm-like microcolony formation.

Authors:  Mauricio Alvarez; Carolyn Saylor; Arturo Casadevall
Journal:  Cell Microbiol       Date:  2008-04-01       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.